Some groups recommend that, in patients who develop RCC at <46 years old, germline testing for BAP1 mutations may identify earlier BAP1-tumor predisposition syndrome patients and offer better surveillance [28]. This evidence concerns the gene BAP1 and renal cell carcinoma.